Biosimilars
30 results
Applied filters
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
Good governance when implementing natalizumab biosimilar
11 December 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
The licence and supporting evidence for natalizumab biosimilar
14 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Biosimilars
Regularly updated material to support the introduction of aflibercept, golimumab, ranibizumab, ustekinumab and other biosimilars of interest.
National Homecare Medicines Committee (NHMC) Homecare Risk Assessment
10 December 2019Find attached the homecare risk assessment spreadsheet to download
NHMC Good Practice Principles for the Provision of Manufacturer Funded Homecare Services
5 March 2018Find attached the good practice principles for manufacturers offering manufacturer funded homecare medicine services